- Home
- WF vs EXEL Comparison
WF vs EXEL Comparison
Compare WF & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WF | EXEL |
|---|---|---|
| Founded | 1899 | 1994 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 12.7B |
| IPO Year | 2003 | 2000 |
Fundamental Metrics
Financial Performance| Metric | WF | EXEL |
|---|---|---|
| Price | $73.63 | $54.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 21 |
| Target Price | N/A | ★ $46.50 |
| AVG Volume (30 Days) | 72.4K | ★ 2.5M |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | N/A | ★ 1.60 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $18.73 | $13.61 |
| Revenue Next Year | $4.33 | $13.13 |
| P/E Ratio | ★ $9.03 | $34.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.83 | $33.76 |
| 52 Week High | $84.71 | $57.57 |
Technical Indicators
Market Signals| Indicator | WF | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 66.23 | 52.06 |
| Support Level | $66.20 | $54.30 |
| Resistance Level | $74.83 | $57.12 |
| Average True Range (ATR) | 1.29 | 1.34 |
| MACD | 0.04 | 0.32 |
| Stochastic Oscillator | 100.00 | 68.90 |
Price Performance
Historical ComparisonAbout WF Woori Financial Group Inc. (each representing three (3) shares of)
Woori Financial Group Inc is a banking and financial services holding company that offers a wide range of businesses, including corporate banking, consumer banking, credit card operations, investment banking, capital markets activities, international banking, asset management, life insurance, and other businesses. It provides products and services to customers, which mainly comprise small- and medium-sized enterprises and individuals, as well as some of Korea's corporations. It has six operational business segments: banking, life insurance, credit card, capital, investment securities, and other operations.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.